Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Precision BioSciences Inc. on April 8, 2021, regarding events occurring on that date. The Company is a Delaware corporation with its principal executive offices in Durham, North Carolina, and its common stock trades on the Nasdaq Global Select Market under the symbol "DTIL". The Company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change reported is the appointment of Stanley R. Frankel, M.D., to the Board of Directors as a Class II director and as a member of the Science and Technology Committee, effective April 12, 2021. Dr. Frankel brings significant expertise in drug development, specifically in hematologic malignancies, immuno-oncology, and cellular therapies, having previously held senior leadership roles at Bristol-Myers Squibb Co. and Celgene Corp.
Guidance, Outlook, and Compensation
The filing details the compensation package for the new director under the Non-Employee Director Compensation Program:
- Annual Cash Retainer: $40,000, earned quarterly.
- Initial Equity Award: Options with an aggregate grant date fair value of $350,000, vesting over 36 months.
- Annual Equity Award: Options with an aggregate grant date fair value of $175,000, granted at the annual meeting (subject to service requirements), vesting within one year.
Dr. Frankel is expected to enter into the Company's standard form indemnification agreement. The filing does not contain specific guidance, outlook, or risk factors beyond the standard disclosure of the director's appointment.
Key Facts for Investor Verification
- Confirm the effective date of Dr. Frankel's board service (April 12, 2021) and his term expiration (2021 annual meeting).
- Verify the total potential equity compensation value ($525,000 in grant date fair value) and the specific vesting schedules.
- Review Dr. Frankel's prior employment history at Bristol-Myers Squibb and Celgene for potential conflicts of interest or strategic alignment.
- Check the Company's latest 10-K or 10-Q for financial metrics, as this 8-K does not contain financial data.